These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 25936328

  • 1. Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment.
    Schampera S, Fischer S, Weiss N, Julius U.
    Atheroscler Suppl; 2015 May; 18():209-14. PubMed ID: 25936328
    [Abstract] [Full Text] [Related]

  • 2. Actual situation of lipoprotein apheresis in Saxony in 2013.
    Emmrich U, Hohenstein B, Julius U.
    Atheroscler Suppl; 2015 May; 18():215-25. PubMed ID: 25936329
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease.
    Heigl F, Hettich R, Lotz N, Reeg H, Pflederer T, Osterkorn D, Osterkorn K, Klingel R.
    Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):8-13. PubMed ID: 25672934
    [Abstract] [Full Text] [Related]

  • 5. Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run.
    Groß E, Hohenstein B, Julius U.
    Atheroscler Suppl; 2015 May; 18():226-32. PubMed ID: 25936330
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of lipoprotein apheresis on PCSK9 levels.
    Julius U, Milton M, Stoellner D, Rader D, Gordon B, Polk D, Waldmann E, Parhofer KG, Moriarty PM.
    Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324
    [Abstract] [Full Text] [Related]

  • 8. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
    Klingel R, Heibges A, Fassbender C.
    Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
    [Abstract] [Full Text] [Related]

  • 9. Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study.
    Schatz U, Tselmin S, Müller G, Julius U, Hohenstein B, Fischer S, Bornstein SR.
    Atheroscler Suppl; 2017 Nov; 30():246-252. PubMed ID: 29096845
    [Abstract] [Full Text] [Related]

  • 10. The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.
    Schettler VJJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, Grützmacher P, Blume H, Vogt A, Scientific Board of GLAR for the German Apheresis Working Group.
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):44-49. PubMed ID: 28233268
    [Abstract] [Full Text] [Related]

  • 11. The incidence of cardiovascular events is largely reduced in patients with maximally tolerated drug therapy and lipoprotein apheresis. A single-center experience.
    Sampietro T, Sbrana F, Bigazzi F, Ripoli A, Dal Pino B, Pasanisi EM, Petersen C, Coceani M, Luciani R, Pianelli M.
    Atheroscler Suppl; 2015 May; 18():268-72. PubMed ID: 25936336
    [Abstract] [Full Text] [Related]

  • 12. Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.
    Schettler VJJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, Grützmacher P, Blume H, Scientific Board of GLAR for the German Apheresis Working Group.
    Atheroscler Suppl; 2017 Nov; 30():50-55. PubMed ID: 29096861
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines.
    Klingel R, Heibges A, Fassbender C, Pro(a)LiFe-Study Group.
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):38-43. PubMed ID: 28185214
    [Abstract] [Full Text] [Related]

  • 17. Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels.
    Ezhov MV, Safarova MS, Afanasieva OI, Pogorelova OA, Tripoten MI, Adamova IY, Konovalov GA, Balakhonova TV, Pokrovsky SN.
    Atheroscler Suppl; 2015 May; 18():163-9. PubMed ID: 25936321
    [Abstract] [Full Text] [Related]

  • 18. Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy?
    Heigl F, Pflederer T, Klingel R, Hettich R, Lotz N, Reeg H, Schettler VJJ, Roeseler E, Grützmacher P, Hohenstein B, Julius U.
    Atheroscler Suppl; 2019 Dec; 40():23-29. PubMed ID: 31818446
    [Abstract] [Full Text] [Related]

  • 19. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
    Hohenstein B, Julius U, Lansberg P, Jaeger B, Mellwig KP, Weiss N, Graehlert X, Roeder I, Ramlow W.
    Atheroscler Suppl; 2017 Nov; 30():180-186. PubMed ID: 29096835
    [Abstract] [Full Text] [Related]

  • 20. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.
    Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Leebmann J, Lehmacher W, Kamstrup PR, Nordestgaard BG, Maerz W, Noureen A, Schmidt K, Kronenberg F, Heibges A, Klingel R, Pro(a)LiFe-Study Group.
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):2019-27. PubMed ID: 27417585
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.